Company Profile
Hansa Biopharma AB (publ), a biopharmaceutical company provides development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe.
The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.
It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. Additionally, it evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation.
It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD) and R&D collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies.
Hansa Biopharma AB (publ) was formerly known as Hansa Medical AB (publ) and changed its name to Hansa Biopharma AB (publ) in December 2018. Incorporated in 2007, Hansa Biopharma AB (publ) is headquartered in Lund, Sweden.